OTHR-37. Pediatrics Cutaneous Reactions in Patient Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib

OBJECTIVE: To describe the cutaneous adverse effects (AE) to MAPK Extracellular Signal-Regulated Kinase (MEK) Inhibitor Trametinib in the pediatric population. METHODS: This was a retrospective single-center study. Included were all pediatric patients, treated with trametinib, for an oncologic indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gluck, Mirit, Ben-amitai, Dan, Friedland, Rivka, Toledano, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Others (Not Fitting Any Other Category)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164969/
http://dx.doi.org/10.1093/neuonc/noac079.575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164969/
http://dx.doi.org/10.1093/neuonc/noac079.575

Ejemplares similares